Skip to main content
Erschienen in: International Urogynecology Journal 7/2017

06.12.2016 | Original Article

Mesh removal after vaginal surgery: what happens in the UK?

verfasst von: Jonathan Duckett, Roland Morley, Ash Monga, Tim Hillard, Dudley Robinson

Erschienen in: International Urogynecology Journal | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

There is little objective evidence regarding complication rates for mesh procedures outside clinical trials. Current coding poorly collects complications of prolapse and continence surgery using mesh. This survey was designed to identify surgeons performing mesh removal and reporting patterns in the UK.

Methods

An electronic questionnaire was sent to all members of the Royal College of Obstetricians and Gynaecologists and members of the Section of Female Neurological and Urodynamic Urology of the British Association of Urologists in the UK. The questionnaire aimed to identify the number of procedures performed for mesh complications and whether they were reported to the Medicines and Healthcare products Regulatory Agency (MHRA) and the patterns of referral and treatment

Results

Referral to a colleague in the same hospital was common practice (69 %). Only 27 % of respondents stated that they reported all removals to the MHRA. The numbers of surgical procedures were low, with most respondents performing between one and three procedures each year and many not performing any surgery for a specific mesh complication in the previous year.

Conclusions

Removal of exposed, eroded and/or painful vaginally inserted mesh is performed by many different surgeons in a variety of hospital settings in the UK.
Literatur
1.
Zurück zum Zitat Jelovesk J, Barber M. Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol. 2006;194:1455–1461.CrossRef Jelovesk J, Barber M. Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol. 2006;194:1455–1461.CrossRef
2.
Zurück zum Zitat Novara G, Artibani W, Barber M, et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol. 2010;58:218–238.CrossRefPubMed Novara G, Artibani W, Barber M, et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol. 2010;58:218–238.CrossRefPubMed
4.
Zurück zum Zitat US Food and Drug Administration. Safety Communications. Update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. Spring Harbor, MD: Food and Drug Administration; 2011. US Food and Drug Administration. Safety Communications. Update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. Spring Harbor, MD: Food and Drug Administration; 2011.
5.
Zurück zum Zitat Ulmsten U, Petros P. Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence. Scand J Urol Nephrol. 1995;29:75–82.CrossRefPubMed Ulmsten U, Petros P. Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence. Scand J Urol Nephrol. 1995;29:75–82.CrossRefPubMed
8.
Zurück zum Zitat Medicines and Healthcare products Regulatory Agency. A summary of the evidence on the benefits and risks of vaginal mesh implants. London: Medicines and Healthcare products Regulatory Agency; 2014. Medicines and Healthcare products Regulatory Agency. A summary of the evidence on the benefits and risks of vaginal mesh implants. London: Medicines and Healthcare products Regulatory Agency; 2014.
9.
Zurück zum Zitat Chief Medical Officer and Public Health Directorate. Transvaginal mesh implants (letter from the Acting Chief Medical Officer, A. Keel). Edinburgh: The Scottish Government; 2014. Chief Medical Officer and Public Health Directorate. Transvaginal mesh implants (letter from the Acting Chief Medical Officer, A. Keel). Edinburgh: The Scottish Government; 2014.
10.
Zurück zum Zitat Chughtai B, Mao J, Buck J, Kaplan S, Sedrakyan A. Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study. BMJ. 2015;350:h2685.CrossRefPubMedPubMedCentral Chughtai B, Mao J, Buck J, Kaplan S, Sedrakyan A. Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study. BMJ. 2015;350:h2685.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat National Institute for Health and Care Excellence. Urinary incontinence in women: management. CG171. London: National Institute for Health and Care Excellence; 2013. National Institute for Health and Care Excellence. Urinary incontinence in women: management. CG171. London: National Institute for Health and Care Excellence; 2013.
Metadaten
Titel
Mesh removal after vaginal surgery: what happens in the UK?
verfasst von
Jonathan Duckett
Roland Morley
Ash Monga
Tim Hillard
Dudley Robinson
Publikationsdatum
06.12.2016
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 7/2017
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3217-z

Weitere Artikel der Ausgabe 7/2017

International Urogynecology Journal 7/2017 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.